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Recently, new information relating to the potential relevance of chronic hepatic inﬂammation to the development and progression
of hepatocellular carcinoma (HCC) has been generated. Persistent hepatocellular injury alters the homeostatic balance within
the liver; deregulation of the expression of factors involved in wound healing may lead to the evolution of dysplastic lesions into
transformed nodules. Progression of such nodules depends directly on the development and organization of a vascular network,
which provides the nutritional and oxygen requirements to an expanding nodular mass. Angiogenic stimulation promotes intense
structural and functional changes in liver architecture and physiology, in particular, it facilitates transformation of dysplasia
to nodular lesions with carcinogenic potential. HCC depends on the growth and spreading of vessels throughout the tumor.
Because these vascular phenomena correlate with disease progression and prognosis, therapeutic strategies are being developed
that focus on precluding vascular expansion in these tumors. Accordingly, an in-depth study of factors that promote and support
pathological angiogenesis in chronic hepatic diseases may provide insights into methods of preventing the development of HCC
and/or stimulating the regression of established HCC.
1.Introduction
In recent years an appreciable worldwide increase in the inci-
dence of tumors, such as hepatocellular carcinoma (HCC),
has occurred in association with changes in socioeconomic
development, which include potentially relevant changes
in lifestyles [1]. Development of HCC is known to be
triggered by factors that lead to chronic hepatic injury
and deregulation of the normal process of wound healing,
which promote persistent stimulation of proﬁbrotic and
proangiogenic processes that lead to signiﬁcant structural
changes in the liver and functional changes in hepatic
physiology [2].
Formation of new blood vessels (angiogenesis) is closely
related to the development of HCC. Indeed, HCC is a
highly vascularized tumor, a feature that has implications for
investigative procedures applied for its detection [3]. Among
features of the vasculature of the liver, not found in other
tissues, are the hepatic sinusoids, characteristics of which
include the presence of hepatic sinusoidal endothelial cells
(LSECs) that possess distinctive fenestrations and pericytes
or hepatic stellate cells (HSCs); sinusoids have the ability
to synthesize liver-speciﬁc factors, such as angiopoietin-
like 3 (Angpl3). Angiogenesis in HCC depends on the
same fundamental principles of activation, proliferation and
migration of endothelial cells that occur in other tumors and
diseases in which enhanced angiogenesis occurs [4].
Neoplastic tissue requires a supply of oxygen and nutri-
ents. Thus, avascular solid tumors only grow to a certain
size and then undergo regression, if their metabolic demands
are not met [5]. For continued growth, it is necessary for a
tumor to orchestrate the formation of a functioning system2 Journal of Oncology
of blood vessels, which allows the delivery of metabolites
(including growth factors) and cells (immunological cells
and other cellular precursors) to the tumor environment.
This process involves neo-vascularization of the tumor or
tumor angiogenic switch [6, 7]. Once the requirements
for tumor growth are met as a result of angiogenesis,
the tumor mass then becomes restricted by surrounding
normal tissue, which degenerates and is replaced by tumor
tissue. These phenomena stimulate further immune-driven
angiogenesis; formation of more blood vessels tends to
ameliorate tissue damage. Moreover, spatiotemporal dereg-
ulation of pathological angiogenesis may lead to newly
formed vessels having abnormal architecture and function;
the frequently immature and anomalous characteristics of
tumor vasculature tend to facilitate the spread of tumor cells
[8]. If disseminated tumor cells become located in other
tissues, the whole process of tumorigenesis may reoccur with
the result that secondary tumors are generated (Figure 1).
2. FactorsThat StimulateAngiogenesis
Hypoxia and inﬂammation are the main factors that stim-
ulate angiogenesis. Hypoxia promotes angiogenesis as a
consequence of signalling mediated by hypoxia-inducible
transcription factors [9]. Inﬂammation increases vascular
permeability and promotes chemokine-mediated recruit-
ment of monocytes, macrophages, platelets, mast cells and
other leukocytes that can synthesize angiogenic cytokines
and growth factors [10, 11].
Speciﬁcally, hypoxia impairs the hydroxylation of HIF-
1alpha and hence, reduces its subsequent degradation by
proteasome. Consequently, HIF-1alpha accumulates in the
cytosol, thereby facilitating its interaction with beta subunits
and translocation to the nucleus, with the consequent mod-
ulation of the expression of many angiogenesis-promoting
genes that contain hypoxia-responsive elements (HREs)
(Figure 2).
Furthermore, tissue injury triggers an immune response,
in which immune cells in peripheral blood extravasate
into the damaged tissue, where they mediate restoration
of tissue homeostasis. However, if the injury and associ-
ated inﬂammation persist, continuing endothelial activation
would promote the inﬁltration of immune factors and
cells into the focus of inﬂammation; this process may
stimulatetheproliferationandmigrationofendothelialcells,
the prerequisites for the generation of new blood vessels
(Figure 3)[ 12]. Thus, a close relationship between chronic
inﬂammation, angiogenesis and cancer, recently the subject
of several reviews [13–17], would be expected.
3. Phases of Angiogenesis
The formation of new functional blood vessels depends on
preciseregulationofthemoleculareﬀectorsthatpromotethe
diﬀerent processes involved [13, 14].
Endothelial cell budding is facilitated by vasodilatation,
loosening of interendothelial contacts and leakage from
pre-existing vessels. These phenomena allow extravasation
of plasma proteins that, together with ECM components,
facilitate the laying down of a provisional scaﬀold for
migrating endothelial cells (EC). Nitric oxide (NO), the
angiogenic properties of which have been well characterized
[18–20], is the main factor responsible for vasodilata-
tion. Vascular endothelial growth factor (VEGF) increases
vascular permeability. The basement membrane (mainly
collagen type IV and laminin) and the ECM (collagen
type I and elastin) must undergo degradation to allow
subsequentmigrationandproliferationofEC.Thisprocessis
mediated by speciﬁc proteinases, which include plasminogen
activator. Proteolysis of ECM leads to the exposure of cryptic
epitopes and release of ECM-embedded factors that promote
migration and proliferation of EC [21, 22].
ECs proliferate in response to growth factors secreted
by themselves or by surrounding cells, such as hepatic
stellate cells, leukocytes, hepatocytes and Kupﬀer cells. The
most thoroughly characterized of these growth factors is
VEGF, which is a multifunctional protein that binds to
two tyrosine kinase receptors that are designated kinase
insert domain receptor (KDR) and fms-like tyrosine kinase
receptor (Flt-1) [23]. VEGF, whose promoter contains
hypoxia-inducible factor-responsive elements (HREs), plays
a crucial role virtually in all pathological situations in which
angiogenesis occurs. The therapeutic potential of strategies
aimed at blocking its mechanism of action is currently being
evaluated [24].
A VEGF-induced increase in vascular permeability facili-
tates interchange of metabolites and cells between peripheral
blood and surrounding tissues. The vasculature constitutes
a structural and functional barrier to the transfer of cells
and solutes, which may traverse vascular endothelium by
paracellular and/or transcellular routes [25]. The former
route implies the rupture of intercellular junctions, while the
latter route involves the organization of caveolae or vacuolar
vesicles to generate an intracellular conduit.
VEGF can increase the permeability of the endothe-
lium by enhancing both routes of transfer across vascular
endothelium. Signalling mediated by VEGFR2 promotes
the phosphorylation of vascular endothelial cadherin (VE-
Cadh), which impairs its binding to the actin cytoskeleton
and, hence, leads to deterioration of intercellular junctions.
In addition, this phenomenon is enhanced by VEGF-
mediated dissociation of the VE-PTP phosphatase of VE-
Cadh. Furthermore, the increase of VE-Cadh endocytosis,
as well as the improvement in pathways of transcytosis
mediated by VEGF, may account for associated vascular
integrity and modulation of permeability [26]. As the deliv-
ery of antiangiogenic and antitumor drugs to subendothelial
tumor tissue is promoted by increased vascular permeability,
methodsofmodulatingthetranscellulartransferofdrugsare
being studied in depth with the aim of enhancing the eﬃcacy
of pharmacotherapies for cancer.
In addition to VEGF, proliferation of EC may be
stimulated by other growth factors, such as acidic and
basic ﬁbroblast growth factors (aFGF, and bFGF), hepato-
cyte growth factor (HGF) and transforming growth factor
(TGF) [27–29]. An orderly proliferation of EC leads to theJournal of Oncology 3
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Figure 1: Angiogenic switch: transformed cells proliferate as an avascular nodule until they reach a certain size. Angiogenic switch enables
exponential tumor growth and facilitates dissemination of tumor cells to secondary locations, where pathological angiogenesis may again be
initiated.
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Figure 2: Oxygen-dependent regulation of HIF-1α:i nn o r m a l
oxidative conditions, HIF-1α is hydroxylated and it becomes
ubiquitinated by VHL. Subsequently, HIF-1α is degraded by the
proteasome. In contrast, low oxygen tension leads to stabilization
of HIF-1 and its interaction with beta subunit, which triggers
translocation to the nucleus and modulation of the transcription
of diverse genes that are involved in the response to hypoxia.
f o r m a t i o no fal u m e n[ 30, 31]. A structured 3-dimensional
network of vessels of uniform size then develops, with its
organization being regulated by mechanisms that involve
signalling pathways for determination of branching and
formation of basement membrane and ECM components,
as well as migration of cells and their diﬀerentiation. Mat-
uration of nascent vessels requires recruitment of pericytes,
and formation of a new basement membrane and ECM to
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Figure 3: Innate immunity-driven angiogenesis: immune cells,
mostly neutrophils and monocyte-macrophages, mediate initial
tunnel formation in certain models of angiogenesis. Other myeloid
celltypes,suchasdendriticcells(DCs)andnaturalkillercells(NK),
produceangiogenicfactorsthatattractendothelialcellsthatbecome
essential components of developing blood vessels. Adapted from
Noonan et al., 2008.
provide structural stabilization [31]. Both physical forces
and speciﬁc diﬀerent molecules contribute to these processes
(Figure 4).
Additionally to the induction of proliferation of EC,
eﬀective angiogenesis also requires stabilization of nascent
blood vessels, and formation of interendothelial cell junc-
tions and lumens. Angiopoietin-1 (Ang-1) stabilizes nascent
vessels by binding to the Tie-2 receptor, thereby modulating
junctional molecules [32] and facilitating communication
between EC and mural cells [33]. However, an excess of
Ang-1 increases stiﬀness and inhibits branching of vessels.
Angiopoietin-2(Ang-2)maymediateopposingeﬀects:inthe
absence of VEGF, it antagonizes Ang-1, thereby destabilizing
vessels, inducing death of EC and leading to regression of
vessels; in the presence of VEGF, however, it facilitates the
branching of vessels [33, 34].
Zhang et al. [35] evaluated the expression of angiogenic
factors in specimens of HCC and nonneoplastic hepatic
tissue. They found a higher expression of Ang-2, and lower
expression Ang-1 in HCC than in nonneoplastic tissue,
suggesting that these molecules may play a role in angio-
genesis associated with carcinogenesis and progression of4 Journal of Oncology
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Figure 4: Stages of angiogenesis: angiogenic stimuli, by promoting production of NO and VEGF, lead to dilatation and increased
permeability of blood vessels. Subsequently, other factors, particularly Ang-1, TGF-β, and MMPs, facilitate degradation of basement
membrane and extracellular matrix and detachment of pericytes. Consequently, angiogenic stimuli facilitate proliferation and migration
of endothelial cells. In addition, mesenchymal cells proliferate and diﬀerentiate into pericytes and smooth muscle cells that contribute to the
stabilization of the new blood vessels.
HCC. Pappeti and Herman have reported that pathological
angiogenesis associated with tumors is diﬀerent from that
associated with physiological processes [36]. Under normal
conditions vascular inactivity and stabilization are mediated
by Ang-1, Ang-2, and Tie-2; in pathological angiogenesis
an abnormal Ang-2/Ang-1 ratio, in the presence of VEGF,
plays a critical role in the transformation of noncancerous
liver tissue to HCC by initiating early neovascularization.
Vajkoczy et al. [37] reported that the earliest stage of tumor
development is initiated by VEGF, VEGF receptor-2 and
Ang-2 interacting with host vessels. Therefore, augmented
expression of Ang-2, and downregulation of Ang-1, acting
viatheTie2receptorinthepresenceofVEGF,playimportant
roles in initiating early neovascularization and transforma-
tion of noncancerous hepatic tissue to HCC.
4.Physiological Angiogenesis
Experimental animal models of liver regeneration after par-
tialhepatectomyhave enabledthedevelopment offunctional
sinusoids to be studied. Resection of two thirds of the
total liver mass results in stimulation of quiescent hepa-
tocytes, and activation of numerous transcription factors
that modulate many genes involved in the proliferation of
hepatocytes [38–40]. An exponential increase in the number
ofhepatocytesleadstodeﬁnitivearchitecturalandfunctional
changes in the liver; avascular clusters of cells are generated
that induce the diﬀerentiation and subsequent replication
of the other types of hepatic cells, notably liver sinusoidal
endothelial cells (LSECs), hepatic stellate cells (HSCs), and
other EC precursors mobilized from the bone marrow.
All of these diﬀerent types of cell migrate and interact
with the emerging mass of hepatocytes; they augment
the metabolic functions, including energy metabolism, of
hepatocytes and provide structural support of the maturing
hepatic parenchyma. Subsequently, fullyfunctional sinusoids
are generated about six to eight days after hepatectomy
[41, 42].
5.Pathological HepaticAngiogenesis
While physiological hepatic angiogenesis during liver regen-
eration leads to the formation of new functional sinu-
soids, pathological angiogenesis, which occurs in many
chronic liver diseases, is characterized by the appearance
of capillarized vascular structures [16, 43]( Figure 5). Such
anomalous intrahepatic vascular organization impairs the
physiological interplay between sinusoids and parenchymal
cells. Hepatic injury is exacerbated by enhanced activation
of immunological responses and generation of more intense
hypoxic areas.
Most chronic liver diseases are characterized by diﬀuse,
chronic processes of inﬂammation, necrosis and ﬁbrosis
[2]. Altered mechanisms of chronic wound healing in
response to persistent liver injury lead to an imbalance
in the expression of many cytokines, growth factors andJournal of Oncology 5
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Figure 5: Hepatic angiogenesis: during liver regeneration, newly
formed sinusoids have normal architecture consistent with their
physiological roles. In contrast, pathological hepatic angiogenesis
leads to the capillarization of hepatic sinusoids with the result
that the structure of sinusoids becomes distorted and characteristic
endothelial fenestrations are lost.
metalloproteinases (MMPs), which deregulate pathways of
physiological angiogenesis and, hence, lead to structural and
functional hepatic disorganization [44]. These phenomena
induce accumulation of an excess of extracellular matrix,
the composition of which becomes altered by the deposition
of ﬁbrillar collagen (type I) rather than physiological sinu-
soidal collagen (type IV). Subsequently, the characteristic
fenestrations of LSEC become blocked, and the physiological
interchange of oxygen and metabolic factors is hampered.
The deposition of ﬁbrous tissue increases resistance to blood
ﬂow and, consequently, impairs the delivery of oxygen to the
parenchyma; the resulting tissue hypoxia exacerbates tissue
injury.
Our group described the existence of abnormal vascular
architecture in the liver of patients with autoimmune
hepatitis and primary biliary cirrhosis; these intrahepatic
structural changes were associated with an increase in the
expression of VEGF and angiopoietins [45]. Similar changes
in VEGF and angiopoietins have been reported in the serum
and liver tissue of patients with other chronic liver diseases,
including chronic hepatitis B and, more recently, chronic
hepatitis C [34, 46].
The development of HCC has long been related to
chronic hepatocellular injury. Malignant transformation of
hepatocytes may take place in regenerative nodules that
undergo dysplastic changes. However, a potential con-
tribution of hepatocytic precursors cannot be dismissed.
Uncontrolled proliferation of hepatocytes generates hypoxic
hepaticnodulesthatpromotethestimulationofmechanisms
that mediate the angiogenic switch, a phenomenon that has
both diagnostic and therapeutic relevance [47–49].
In addition to the development of pharmacologic inter-
ventions directed at modulating many of the signalling
routes involved in cell proliferation, survival and invasion
[50], the hypervascular characteristics of HCC have also
encouraged therapeutic approaches that focus on inhibiting
progression of the vascular network present in incipient
malignant nodules and the distinctive tumor vasculature in
established HCC [51, 52]. In many advanced malignancies,
eﬀective delivery of therapeutic drugs to the tumor is limited
by speciﬁc complex features of tumor tissue. Recently,
delivery of pharmacologic agents to malignant nodules has
been enhanced by adopting measures that facilitate the
transcellular route of molecular traﬃcking [53].
In summary, the relevance of chronic hepatocellular
injury to the development of HCC has been emphasized. In
particular, the signiﬁcance of angiogenesis in the progression
of chronic hepatic disease to hepatic malignancies has been
highlighted. A role for deregulation of diﬀerent stages of
angiogenesis in the establishment of advanced tumours and
their subsequent dissemination to other tissues has become
recognized. Accordingly, the in-depth study of regulatory
mechanisms that mediate angiogenesis in pathological con-
ditions would appear to be indicated. One speciﬁc aim
of such an initiative would be to augment the eﬃcacy
of currently available therapies for chronic (inﬂammatory)
hepatic disease and HCC.
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